이번 임상1상은 10여명의 환자를 대상으로 진행됐으며 부작용이 전혀 발견되지 않았으며 환자들에게서 티셀 항체가 형성됐음이 확인됐다.
Phase I clinical trials were conducted on 10 patients, and no side effects were found, and it was confirmed that T cell antibodies had formed in the patients.